Market for SM treatments to rise significantly through 2034, new study says
Increased awareness and diagnosis of SM could increase the growth of the SM pharmaceutical market by 2034.
Increased awareness and diagnosis of SM could increase the growth of the SM pharmaceutical market by 2034.
A recent study assessed the current state of treatments for advanced systemic mastocytosis and the promise of future ones.
A new study detailed a rare case of a man with systemic mastocytosis who presented with symptoms of osteoporosis.
A new case revealed suspected systemic mastocytosis following a female patient’s radiation therapy for breast cancer
Systemic mastocytosis is rare in children, and this case was particularly rare because of its lone symptom.
A case report describes a woman diagnosed with and treated for systemic mastocytosis despite vague symptoms such as atypical skin lesions.
A recent article proposed unifying the 2001 WHO SM diagnostic criteria and revised criteria of the 2021 International Consensus Classification Group.
A new review recommended the use of sensitive mutation detection methods to better diagnose systemic mastocytosis (SM).
A new study suggests that the phenotype of advanced systemic mastocytosis patients might provide clinicians with tools to offer diagnoses and prognoses.
A recent report shows two specific prognostic scoring systems have the most accurate predictive value for advanced SM outcomes.